Corporate Governance

The Quoted Company Alliance (QCA) Code

The Directors recognise the importance of good corporate governance and have chosen to apply the Quoted Companies Alliance Corporate Governance Code (the 'QCA Code'). The QCA Code was developed by the QCA in consultation with a number of significant institutional small company investors, as an alternative corporate governance code applicable to AIM companies. The underlying principle of the QCA code is that "the purpose of good corporate governance is to ensure that the company is managed in an efficient, effective and entrepreneurial manner for the benefit of all shareholders over the longer term". The Directors anticipate that whilst the Company will continue to comply with the QCA Code, given the Group's size and plans for the future, it will also endeavour to have regard to the provisions of the UK Corporate Governance Code as best practice guidance to the extent appropriate for a company of its size and nature. To see how the Company addresses the key governance principles defined in the QCA Code, please refer to the Corporate Governance Report, on pages 54-57 of the Annual Report or available here. Further information on compliance with the QCA Code will be provided in Advanced Oncotherapy plc's next annual report.

Dr Michael Sinclair, Executive Chairman

This disclosure was last reviewed and updated on 28 June 2019.

Responsibilities of the Directors

The Board of Directors meets on a regular basis to review key operational issues, strategic development and the financial performance of the Company. The Board undertakes to represent the intentions of shareholders, investors and key stakeholders. The Board is responsible for internal controls to minimise the risk of financial or operational loss or material misstatement. The list of matters reserved to the Board is available here

Composition of the Board of Directors

The composition of the board is designed to ensure Advanced Oncotherapy has robust and relevant experience from a technology and commercial perspective for a medical device company. The Directors' backgrounds and experiences cover areas of commercial and business development, financial management and control. The full composition of the Board is available here.

Board Committees

The following committees have been established to deal with specific aspects of the Company's affairs, in addition to the usual internal control procedures to govern its routine business activities.

Remuneration Committee

Chairman: Hans von Celsing
Members: Michael Bradfield, Enrico Vanni
Terms of Reference

Audit Committee

Chairman: Hans von Celsing
Members: Michael Bradfield, Enrico Vanni
Terms of Reference

Investor Relations
Investor News Alert Service

Subscribe to our investor alert service and receive all press releases as soon as they become available. Please enter your email address in the box below. You will receive an email confirming your registration.

This Email Alert service is provided by Walbrook PR on behalf of AVO. AVO and Walbrook PR respect your privacy. We promise not to share, rent or sell the information we collect from you, outside of making it periodically available to AVO. Your data is stored securely.